21^st International Conference on Cancer Biology and Cell Science June 13-14, 2022 Amsterdam, Netherlands

Track 1: Cancer

Cancer is a broad term. It describes the disease that results when cellular changes cause the uncontrolled growth and division of cells. Some sorts of cancer cause rapid cell growth, while others cause cells to grow and divide at a slower rate. Certain sorts of cancer end in visible growths called tumors. Most of the body’s cells have specific functions and glued lifespans. A cell death is part of a natural and beneficial phenomenon called apoptosis.
A cell receives instructions to die in order that the body can replace it with a modern cell that functions better. Cancerous cells lack the components that instruct them to stop dividing and to die.
As a result, they build up within the body, using oxygen and nutrients that might usually nourish other cells. Cancerous cells can form tumors, impair the system and cause other changes that prevent the body from functioning regularly.

Track 2: Types of  Cancer & their Management

There are more than 100 types of cancer. Types of cancer are usually named for the organs or tissues where the cancers form. For example, lung cancer starts in the lung, and brain cancer starts in the brain. Cancers also may be described by the type of cell that formed them, such as an epithelial cell or a squamous cell.

Track 3: Diagnosis & Screening of Cancer

Types of cancers are diagnosed with blood tests and biopsies, but people also can need scans to observe the symptoms or see how the treatment is functioning. The tests are getting to be depends on the symptoms and what kind of  cancer being there in  sample.

The detailed information on differing kinds of cancer is diagnosed so if people are worried about they have been diagnosed with a specific kind of cancer. If people have the symptom of screening test result suggests cancer, and also it determine because of cancer or another cause.

Track 4: Treatment of Cancer

There are so many different types of cancer treatments are there with different possible benefits, risks and side effects. Slow-growing cancers can be survived by taking daily medication, whereas people with faster-growing acute  cancers may need stronger (intensive) treatments. A stem cell transplant infuses healthy stem cells into the body.

Chemotherapy is also one of the anticancer drugs designed to interfere with and halt the growth of cancer cells in the body. Cancer cells are destroyed and relieve pain or discomfort by Radiation therapy. It may also be given before a stem cell transplant.

Track 5: Clinical Trials of  Cancer

Clinical trials are nothing but the research studies designed to evaluate devices, new drugs and treatment strategies. With this any of treatment, there are benefits and risks, but joining in a clinical trial can allow us to play a more active role in our own healthcare. Earlier they're widely available to realize new research treatments, and help others by contributing to the body of medical.

Track 6: Advanced Therapies in Cancer

·         Radiofrequency Ablation

·         Cryosurgical Ablation (CSA)

·         Cancer Microvascular Intervention (CMI)

·         NanoKnife Therapy

·         Photodynamic Therapy

·         Immunotherapy

·         Hyperthermia

·         Traditional Chinese Medicine

Track 7: Epidemiology of Cancer

The study of things effecting cancer is named as epidemiology, as how to infer probable trends and causes. Principle period predisposition is the idea that early determination may misleadingly blow up the survival insights of a malignancy, without extremely enhancing the common history of the infection.

The investigation of malignancy the study of epidemiology transmission utilizes epidemiological techniques to discover the reason for tumor and to recognize and create enhanced medications enhancing the regular history of the malady. Length predisposition is that the concept slower developing, more slothful tumors will probably be analyzed by screening tests, however upgrades in diagnosing more instances of sluggish disease might not convert into better patient results after the execution of screening programs. A related concern is over analysis, the inclination of screening tests to analyze illnesses that may not really affect the patient's life span. This issue particularly applies to prostate malignancy and PSA screening.

Track 8:  Cancer Palliative Care & Survivors

Palliative care means care or treatment which will assist you to cure these cancer symptoms. The aim of the palliative care is to offer us an honest quality of life and appearance after the emotional and physical well-being. While tacking other quite treatments for cancer we will still use the palliative care.

The  cancer survivor is the person who is suffering with cancer .
The person becomes a survivor at the time of treatment or after completing diagnosis and actively dying are considered survivors, and whether family members and healthy friends of the cancer patient are considered survivors.
Many cancer survivors describe the method of living with and beating cancer as a life-changing experience. It isn't extraordinary for survivors to utilize the experience as open doors for innovative self-change into a "superior individual" or as inspiration to satisfy objectives of awesome individual significance, for example, climbing a mountain or accommodating with an antagonized relative. This procedure of posttraumatic development is named advantage finding.

Track 9: Radiation Oncology

Radiation Oncology  (radiotherapy/radiation therapy) is a medical specialty that plays an important role in the multimodal treatment of cancer. It works by delivering high-energy x-rays (photons) through a linear accelerator. These painless and undetectable therapeutic x-rays are used to treat a variety of malignancies. The linear accelerator is located in a cancer centre, where a multidisciplinary team of radiation oncologists (your specialist doctor), nurses, radiation therapists, and medical physicists will discuss radiation therapy as a treatment option with you, assess you, plan and deliver your treatment, and assist you with any side effects.

Track 10: Bone Marrow Transplantation and Surgery

Bone Marrow Transplantation: A bone marrow transplant, also known as a haemopoietic stem cell transplant, replaces damaged bone marrow with healthy bone marrow stem cells. Bone marrow is a spongy tissue. A biopsy may be a sample of tissue taken from the body so as to look at it more closely. A doctor should recommend a biopsy when an initial test suggests that a neighborhood of tissue within the body isn't normal. Doctors may call that area of abnormal tissue a lesion, a tumor, or a mass. Topics of discussion in the scientific sessions are Bone Marrow Surgery, Stem Cell Surgery, and Hematopoietic Cell Transplantations.

Track 11: Hemato Immunology & Stem Cell Research

Blood groups are of ABO type and but at present the Rh blood grouping of 50 well defined antigens in which 5 are more important they are D,C,,E and E and Rh factors are of Rh positive and Rh negative which refers to the D-antigen. These D-antigen helps in prevention of erythroblast fatal lacking of Rh antigen it defined as negative and presences of Rh antigen in blood leads to positive these leads to incompatibility. The prevention treatment of diseases related to the cancer is called as the Haematology. The haematologists conduct works on cancer to the disorder of immune system leading to hypersensitivity is called as Clinical Immunology and the abnormal growth of an infection are known as Inflammation and the arise of an abnormal immune response to the body or an immune suppression are known as Auto immune disorder. The stem cell therapy is used to treat or prevent a disease or a condition mostly Bone marrow stem cell therapy is seen and recently umbilical cord therapy Stem cell transplantation strategies remains a dangerous procedure with many possible complications; it is reserved for patients with life-threatening diseases.

Track 12: Cancer Genomics & Metabolomics

Oncogenomics is a sub-field of genomics that characterizes cancer-associated or cancer related genes. It focuses mainly on genomic, epigenomic and transcript alterations in cancer. The main concept and idea of oncogenomics is to check new group of oncogenes or tumor suppressor genes that may give new areas of research into cancer diagnosis, predicting clinical outcome of cancers and new targets for cancer therapies. The Gleevec, Herceptin and Avastin are the targeted cancer therapies which gave a new way for oncogenomics to elucidate new targets for cancer treatment. Metabolomics is a newly emerging field of 'omics' research and refers to the complete set of small- molecules metabolites, which gives the systematic study of unique chemical fingerprints that leaves cellular processes behind. The metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism that are the end biology.

Track 13: Anaemia and Blood Disorders

Weakness may be a condition that makes when your blood needs enough solid red platelets or haemoglobin. Haemoglobin may be a fundamental piece of red platelets and ties oxygen. If you've got unnecessarily few or interesting red platelets, or your hemoglobin is irregular or low, the cells in your body won't get enough oxygen.

Mellow iron deficiency regularly causes no side effects. More extreme pallor can cause exhaustion, fair skin, and shortness of breath with effort. Press inadequacy pallor: Iron is vital for the body to make red platelets. Low iron admission and loss of blood because of feminine cycle are the most widely recognized reasons for press insufficiency paleness.

Regular blood issue incorporate pallor, draining disarranges, for example, hemophilia example, leukemia, lymphoma, and myeloma. On the off chance that you are determined to have a blood issue, your specialist may suggest you to a hematologist.

Track 14: Cell-Based Therapy

Cellular therapies are designed to enhance the immune system's ability to fight cancer. Manufacturing them involves collecting a selected set of cells from the blood, modifying them to supply a more vigorous attack on a patient's cancer cells, then rejecting them into the patient.

Cell-based therapy involves modifying a patient’s own cells or cells from a donor to fight disease and alleviate medical conditions. In recent years, we helped pioneer a landmark cell-based approach, known as chimeric antigen receptor therapy, to treat blood cancers. We continue to investigate an expanding array of cell types for novel therapeutic uses.

Track 15: Advancement in the field of cancer

Cancer is an increasing explanation for morbidity and mortality in most countries. “Breakthroughs” in cancer research are reported regularly in the media. Some reports are supported new results that show potential for improved treatments, but others are premature or publicity seeking, and therefore the motivation behind them is questionable. The public has high expectations that basic science cancer research will translate into improved cancer cures and care. Yet awareness and understanding of the clinical trials that are essential in establishing the effectiveness of latest treatments is restricted. Recruitment to randomized clinical trials evaluating new cancer treatments is often slow, partly because people are convinced that all new treatments are likely to be an improvement and partly because of unease about the process of randomization. Better public education about categories of evidence in reference to health interventions might contribute to speedier and more appropriate evaluation of promising treatments.

Track 16: Chemical Biology

Chemical biology investigates the use of chemical tools to study and manipulate biological systems. Small molecules probe and target specific cellular processes, inhibiting or boosting the effects of proteins and other molecules. This allows us to clarify these mechanisms analyze the groundwork for the development of drugs that can slow or reverse disease.

Track 17: Computational Oncology

 Next-generation sequencing has enabled scientists to collect an astonishing amount of data about the genomes of both normal and cancerous cells. Through computational oncology, our investigators are creating tools that enable them to navigate and analyze this vast quantity of information and translate molecular insights into treatments that can benefit patients.

Computational Oncology is a semi-new phrase that is beginning to gain speed in medicine.  It may be surprising to some to find out that there are full departments being created at large medical institutions across the globe titled as such. 

Track 18: Epigenetics

 Epigenetics refers to inherited information passed down from parent cell to daughter cell but not encoded in the DNA sequence. Some epigenetic changes are a normal part of many biological processes, but other types can lead to disease, including cancer.

It is a chemical modifications of a cell’s genetic material that lead to changes in gene expression without altering the DNA sequence. Over the past few years, we have learned that epigenetic mechanisms play a critical role in the initiation, development, and progression of many types of cancer. Unlike genetic mutations, epigenetic states are in many cases reversible, which means it may be possible to manipulate them with drugs to interfere with tumor-promoting cell processes. The goal of the CER is to explore how epigenetic processes integrate cellular signaling and the metabolic state to influence cell proliferation, differentiation, and adaptation during both normal development and cancer. This research is providing new insights into cancer pathogenesis and unique opportunities for developing new therapeutic strategies.

Track 19: Cancer Health Disparities

There has been substantial progress in cancer treatment, screening, diagnosis, and prevention over the past several decades, addressing cancer health disparities—such as higher cancer death rates, less frequent use of proven screening tests, and higher rates of advanced cancer diagnoses—in certain populations is an area in which progress has not kept pace.

These disparities are frequently seen in people from low-socioeconomic groups, certain racial/ethnic populations, and those who live in geographically isolated areas.

 

The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026. Cancer therapeutics involves the use and administration of chemotherapy and oncology drugs to treat cancer.

Increase in cancer prevalence, surge in collaboration between pharmaceutical companies, and rise in cancer research are the key factors that augment the growth of the cancer therapeutics market. Furthermore, growth in geriatric population is expected to boost the market growth.

However, high cost associated with oncology drug development along with adverse effects associated with cancer therapeutics are some of the factors that restrain the market growth. Conversely, the upsurge in demand for personalized medicine and high potential of developing nations is expected to provide new opportunities for the market players in future.

The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Cancer Therapeutics Market:

·         The report entails a detailed quantitative cancer therapeutics market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.

·         Market size and estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.

·         An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.

·         The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

       

Scientists and Researchers organizers

Directors of Oncology department

Hospitals and Healthcare professionals

Oncologist

Pathologist

Microbiologist

Pharmaceutical companies

Genetics Associations and Societies

Doctors

Research scholars

Academic researchers

Professors

Business delegates

Young Researchers

Advertising and Promotion Agency Executives

Medical & Pharmaceutical Companies

Biomedical Research organizations, societies and associations

Software developing companies

Data Management Companies

Student Carrying out Laboratory and Field Studies

 

Young Scientists Benefit

• Our conferences provide an excellent Platform for your research through oral presentations.
• Share ideas with leading researchers and consultants.
• Young Scientist Award re-certification certificate and a reminder to the winners
• Junior Scientists will receive relevant and up-to-date information on this Forum.
• A collaborative platform among junior investigators for better development
• The award should encourage participants to strive for their full potential which can be beneficial to the whole sector

 

Why to attend

To network

A big reason for attending the conference is to meet with likeminded people and industry peers. This conferences bring together people from all different geographical areas who share a common discipline or field, and they are a great way to meet new people in your field.

To expand your knowledge and find solutions to problems

You will hear a lot about things in your field that will be new to you. These could be new techniques, new types of equipment, unpublished data, or learn from thought-leaders that you may not have previously heard of.

 To present your ideas and work to others

This is one of the more obvious reasons for attending conference to present your work. It’s good practice in talking about what you do with a variety of people from similar, related and/or completely different areas of study.